THERAPEUTICS
Review: evidence for major benefits and harms of antidiabetic agents for diabetes with heart failure is limited
| The first 150 words of the full text of this article appear below. |
A Johnson
Dr A Johnson, University of Alberta, Edmonton, Alberta, Canada; jeff.johnson@ualberta.ca
REVIEW PROCESS
in patients with heart failure (HF) and diabetes, what is the relation between antidiabetic therapy and morbidity and mortality?
Medline (1966–2007), EMBASE/Excerpta Medica (1980–2007), Cochrane Central Register of Controlled Trials (1991–2007), 5 other databases, reference lists, and experts.
randomised controlled trials (RCTs) or cohort studies evaluating the association between antidiabetic drugs (insulin, metformin [MET], sulphonylurea [SU], and thiazolidinedione [TZD]) and hospital admission or all-cause mortality in patients with HF and diabetes. Quality assessment of individual studies was based on a validated checklist (maximum score 32; scores
12 indicate acceptable quality). 8 studies met the selection criteria: 1 RCT, 2 posthoc analyses from RCTs, 4 retrospective cohort studies, and 1 prospective cohort study; quality scores ranged from 13–22.
all-cause hospital admission, hospital admission for HF (cardiovascular morbidity), and all-cause mortality. Meta-analysis was not done because of significant statistical heterogeneity
University of Florida, Gainesville, Florida, USA
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
